Review article: Diagnosis and management of night-time reflux

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 9, 2004, Pages 57-72

  McGuigan, J E ^a   Belafsky, P C ^b   Fromer, L ^c   McCarthy, D ^d   Nostrant, T ^e   Postma, G N ^f   Welage, L S ^e   Wolfe, M M ^g  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AROUSAL; DISEASE SEVERITY; ENDOSCOPY; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HUMAN; LIFESTYLE; LUNG COMPLICATION; NIGHT; PH MEASUREMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT INDICATION;

EID: 10644240761     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02241.x     Document Type: Review

References (102)

1. Locke GRI, Talley NJ, Fett SL, Zinsmeister AR, Melton LJI. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County. Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000; 45: 809-18.
3. Shaker R, Castell DO, Schoenfeld P, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-93.
4. Cibella F, Cuttitta G. Nocturnal asthma and gastroesophageal reflux. Am J Med 2001; 111(Suppl. 8A): S31-6.
5. Gislason T, Janson C, Vermeire P, et al. Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. Chest 2002; 121: 158-63.
6. Harding SM. Nocturnal asthma: role of nocturnal gastroesophageal reflux. Chronobiol Int 1999; 16: 641-62.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
8. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.
9. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 2003; 48: 2237-41.
10. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101: 1-78.
11. Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis 1981; 123: 413-7.
12. Batch AJ. Globus pharyngeus: (Part II), Discussion. J Laryngol Otol 1988; 102: 227-30.
13. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100: 395-405.
14. Larrain A, Carrasco E, Galleguillos F, Sepulveda R, Pope CE. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 1330-5.
15. Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162: 34-9.
16. Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003; 17: 1309-17.
17. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
18. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 837-47.
19. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15-20.
20. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
21. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 261-73.
22. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-27.
23. Shaheen N, Ransohoff DF. Gastroesophageal reflux. Barrett esophagus, and esophageal cancer: scientific review. J Am Med Assoc 2002; 287: 1972-81.
24. Dean R, Dua K, Massey B, Berger W, Hogan WJ, Shaker R. A comparative study of unsedated transnasal esophagogastroduodenoscopy and conventional EGD. Gastrointest Endosc 1996; 44: 422-4.
25. Dobhan R, Castell DO. Normal and abnormal proximal esophageal acid exposure: results of ambulatory dual-probe pH monitoring. Am J Gastroenterol 1993; 88: 25-9.
26. Fisher RS, Sher DJ, Donahue D, Senior J, Krevsky B. A single intragastric pH electrode does not accurately measure intragastric acidity. Am J Gastroenterol 1996; 91: 1167-72.
27. Anggiansah A, Sumboonnanonda K, Wang J, Linsell J, Hale P, Owen WJ. Significantly reduced acid detection at 10 centimeters compared to 5 centimeters above lower esophageal sphincter in patients with acid reflux. Am J Gastroenterol 1993; 88: 842-6.
28. Postma GN. Ambulatory pH monitoring methodology. Ann Otol Rhinol Laryngol Suppl 2000; 184: 10-4.
29. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci 1981; 26: 673-80.
30. Sigmund CJ, McNally EF. The action of a carminative on the lower esophageal sphincter. Gastroenterology 1969; 56: 13-8.
31. Wendl B, Pfeiffer A, Pehl C, Schmidt T, Kaess H. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment Pharmacol Ther 1994; 8: 283-7.
32. Pehl C, Wendl B, Pfeiffer A, Schmidt T, Kaess H. Low-proof alcoholic beverages and gastroesophageal reflux. Dig Dis Sci 1993; 38: 93-6.
33. Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 1988; 83: 633-6.
34. Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994; 89: 509-12.
35. Orr WC, Heading R, Johnson LF, Kryger M. Sleep and its relationship to gastroesophageal reflux. Aliment Pharmacol Ther 2004; 20(Suppl. 9): 39-46.
36. Hamilton MI, Sercombe J, Pounder RE. Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine. Aliment Pharmacol Ther 2001; 15: 1579-83.
37. Bruley des Varannes S, Duquesnoy C, Mamet JP, Slama A, Galmiche JP, Scarpignato C. Effects of tablet and effervescent formulations of ranitidine 75 mg and cimetidine 200 mg on gastric acidity and oesophageal acid exposure in healthy humans. Aliment Pharmacol Ther 1998; 12: 1155-61.
38. Shin JM, Besancon M, Simon A, Sachs G. The site of action of pantoprazole in the gastric H+/K(+)-ATPase. Biochim Biophys Acta 1993; 1148: 223-33.
39. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 4438-46.
40. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
41. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole. the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-26.
42. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9-31.
43. Simon TJ, Berlin RG, Gardner AH, Stauffer LA, Gould AL, Getson AJ. Self-directed treatment of intermittent heartburn: a randomized, multicenter, double-blind, placebo-controlled evaluation of antacid and low doses of an H(2)-receptor antagonist (famotidine). Am J Ther 1995; 2: 304-13.
44. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Baillieres Best Pract Res Clin Gastroenterol 2001; 15: 355-70.
45. Robinson M, Rodriguez-Stanley S, Ciociola AA, et al. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther 2001; 15: 1365-74.
46. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000: 95: 57-61.
47. Wilder-Smith C, Halter F, Ernst T, et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 15-27.
48. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35: 976-83.
49. Fullarton GM, McLauchlan G, Macdonald A, Crean GP, McColl KE. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 1989; 30: 449-54.
50. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
51. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
52. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 2001; 36(Suppl. 234): 3-9.
53. De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91: 333-7.
54. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855-70.
55. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-8.
56. Welage LS. Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. Gastroenterol Clin North Am 2003; 32: S25-S35.
57. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Effective intra-oesophageal acid suppression in patients with gastrooesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 2003; 17: 235-41.
58. Richter JE, Kahrilas PJ, Johanson J, et al. for the Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
59. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089-98.
60. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704-10.
61. Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
62. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology 1992; 102: 109-18.
63. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91: 1749-57.
64. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18: 587-94.
65. Kovacs TO, Wilcox CM, DeVault K, Miska D, Bochenek W. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 2002; 16: 2043-52.
66. Metz DC, Bochenek WJ. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003; 17: 155-64.
67. Kahrilas PJ, Falk GW, Johnson DA, et al. for the Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-58.
68. Castell DO, Kahrilas PJ. Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
69. Kovacs TOG, Wilcox CM, DeVault K, et al. Comparison of the efficacy of pantoprazole versus nizatidine in the treatment of erosive esophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 2002; 16: 2043-52.
70. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 445-54.
71. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998-1017.
72. DiMarino AJ Jr, Banwait KS, Eschinger E, Greenberg A, Doghramji K, Cohen S. Sleep efficiency: effect of PPI therapy in patients with marked sleep disturbance. Gastroenterology 2004; 126(Suppl. 2): A-340.
73. Banwait KS, Greenberg A, Eschinger E, Doghramji K, Cohen S, DiMarino AJ. The effect of proton pump therapy on disturbed sleep mechanics induced by esophageal acid exposure. Gastroenterology 2004; 126(Suppl. 2): A-335.
74. Johnson D, Orr W, Cuccia A, Traxler B, Brown K, Roth T. Esomeprazole for the relief of moderate to severe nighttime heartburn and associated sleep disturbance in patients with GERD: a multicenter, randomized, double-blind, placebo-controlled, 4-week study. Gastroenterology 2004; 126(Suppl. 2): A-336.
75. Stalhammar NO, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999; 16: 483-97.
76. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095-100.
77. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 1940-4.
78. McGuigan JE. Treatment of gastroesophageal reflux disease: to step or not to step. Am J Gastroenterol 2001; 96: 1679-81.
79. Metz DC. Therapy for gastroesophageal reflux disease: more is not necessarily better. Am J Gastroenterol 2003; 98: 1913-5.
80. Barrison AF, Jarboe LA, Weinberg BM, Nimmagadda K, Sullivan LM, Wolfe MM. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001; 111: 469-73.
81. APhA. APhA and Prevention magazine national survey shows too many Americans put themselves at risk through self-medication. 2004: http://www.aphanet.org/
82. Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-8.
83. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40: 52-62.
84. McCarthy DM, McLaughlin TP, Griffls DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther 2003; 10: 330-40.
85. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
86. McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
87. Castell DO, Sigmund C Jr, Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998; 93: 547-52.
88. McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984; 79: 165-72.
89. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
90. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.
91. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 1532-8.
92. Delchier JC, Cohen G, Humphries TJ. Rabeprazole. 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol 2000; 35: 1245-50.
93. Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 2001; 111: 979-81.
94. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002; 127: 32-5.
95. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
96. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
97. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. This work was presented in part as an oral communication at Digestive Disease Week, Atlanta, GA, May 21-23, 2001. Am J Gastroenterol 2003; 98: 545-50.
98. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
99. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
100. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502-7.
101. Richter JE. Ambulatory oesophageal pH monitoring. Am J Med 1997; 103: S130.
102. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995; 56: 443-54.